Electra Therapeutics, Inc. (ETRA)

Data as of Sep 23, 2026, from SEC Form 4 filings.

Net insider buying (90d)Watch ETRA

See up to 3 months of ETRA. The 7-day demo opens the 1M and 3M ranges and puts ETRA on your watchlist.

Latest ETRA insider trades

Carl L. Gordon - Director
Open-market purchase$5.00M
Sep 21, 2026
Carl L. Gordon - Director
Open-market purchase

About Electra Therapeutics, Inc. (ETRA)

The SEC lists Electra Therapeutics, Inc. under CIK 0002088082, in biological products (no diagnostic substances). It is grouped with Health Care companies on this site. Its offering priced on 18 September 2026 and it trades on NASDAQ.

Sector: Health Care

SEC filings for ETRA on EDGAR

ETRA Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Open-market purchase	4	2,666,666	$40.00M
Other acquisition / disposition	24	23,927,906

Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.

ETRA insider transactions (Form 4)

6 Form 4 filings on record, the earliest from Sep 21, 2026, newest first.

Traded	Insider	Transaction	Security	Shares	Price	Value
Sep 21, 2026	Carl L. Gordon - Director	Other	Common Stock	2,002,310	-^{footnote F1}	-
Sep 21, 2026	Carl L. Gordon - Director	Other	Common Stock	1,087,934	-^{footnote F1}	-
Sep 21, 2026	Carl L. Gordon - Director	Other	Common Stock	1,703,314	-^{footnote F1}	-
Sep 21, 2026	Carl L. Gordon - Director	Open-market purchase	Common Stock	333,333^{footnote F2}	$15.00	$5.00M
Sep 21, 2026	Carl L. Gordon - Director	Other	Common Stock	758,279	-^{footnote F1}	-
Sep 21, 2026	Carl L. Gordon - Director	Open-market purchase	Common Stock	1,000,000^{footnote F2}	$15.00	$15.00M
Sep 21, 2026	Carl L. Gordon - Director	Other	Series A Convertible Preferred Stock	2,002,310	$0.00	-
Sep 21, 2026	Carl L. Gordon - Director	Other	Series B Convertible Preferred Stock	1,087,934	$0.00	-
Sep 21, 2026	Carl L. Gordon - Director	Other	Series C Convertible Preferred Stock	1,703,314	$0.00	-
Sep 21, 2026	Carl L. Gordon - Director	Other	Series C Convertible Preferred Stock	758,279	$0.00	-
Footnote F1 (price): Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering… Full note on SEC EDGAR Footnote F2 (shares): Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
Sep 21, 2026	ORBIMED ADVISORS LLC - Director	Other	Common Stock	2,002,310	-^{footnote F1}	-
Sep 21, 2026	ORBIMED ADVISORS LLC - Director	Other	Common Stock	1,087,934	-^{footnote F1}	-
Sep 21, 2026	ORBIMED ADVISORS LLC - Director	Other	Common Stock	1,703,314	-^{footnote F1}	-
Sep 21, 2026	ORBIMED ADVISORS LLC - Director	Open-market purchase	Common Stock	333,333^{footnote F2}	$15.00	$5.00M
Sep 21, 2026	ORBIMED ADVISORS LLC - Director	Other	Common Stock	758,279	-^{footnote F1}	-
Sep 21, 2026	ORBIMED ADVISORS LLC - Director	Open-market purchase	Common Stock	1,000,000^{footnote F2}	$15.00	$15.00M
Sep 21, 2026	ORBIMED ADVISORS LLC - Director	Other	Series A Convertible Preferred Stock	2,002,310	$0.00	-
Sep 21, 2026	ORBIMED ADVISORS LLC - Director	Other	Series B Convertible Preferred Stock	1,087,934	$0.00	-
Sep 21, 2026	ORBIMED ADVISORS LLC - Director	Other	Series C Convertible Preferred Stock	1,703,314	$0.00	-
Sep 21, 2026	ORBIMED ADVISORS LLC - Director	Other	Series C Convertible Preferred Stock	758,279	$0.00	-
Footnote F1 (price): Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering… Full note on SEC EDGAR Footnote F2 (shares): Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
Sep 21, 2026	Gary S. Koe - Officer	Other	Common Stock	63,656	-^{footnote F1}	-
Sep 21, 2026	Gary S. Koe - Officer	Other	Series A Convertible Preferred Stock	63,656	-^{footnote F1}	-
Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The… Full note on SEC EDGAR
Sep 21, 2026	Nancy Stagliano - Director	Other	Common Stock	255,635	-^{footnote F1}	-
Sep 21, 2026	Nancy Stagliano - Director	Other	Series A Convertible Preferred Stock	255,635	-^{footnote F1}	-
Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The… Full note on SEC EDGAR
Sep 21, 2026	Graham Parry - Officer	Other	Common Stock	85,504^{footnote F1}	-^{footnote F2}	-
Sep 21, 2026	Graham Parry - Officer	Other	Series A Convertible Preferred Stock	85,504^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): 7,125 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/4th of the Restricted Shares shall vest monthly commencing from September 2, 2026. Footnote F2 (price): Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The… Full note on SEC EDGAR
Sep 21, 2026	Quehuong (Kathy) Dong - Officer	Other	Common Stock	455,484^{footnote F1}	-^{footnote F2}	-
Sep 21, 2026	Quehuong (Kathy) Dong - Officer	Other	Series A Convertible Preferred Stock	455,484^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): 73,147 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/13th of the Restricted Shares shall vest monthly commencing from September 16, 2026. Footnote F2 (price): Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The… Full note on SEC EDGAR

Recent ETRA Form 8-K filings

Read ETRA company news

Sep 21, 2026Item 5.03, 8.01, 9.01

Read the filing on SEC EDGAR

ETRA insider trading FAQ

What is the latest insider trade for ETRA?

Electra Therapeutics, Inc. (ETRA) had 6 insider filings in the last 90 days, with the most recent on 23 September 2026. The full record for ETRA runs to 6 Form 4 filings, the earliest from 21 September 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying ETRA stock?

4 insider purchases of ETRA were filed in the last 90 days, totaling $40.00M.

How many insiders are selling ETRA stock?

No insider sales of ETRA were filed in the last 90 days.

Where can I see ETRA SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects ETRA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Sep 23, 2026 - Carl L. Gordon view on EDGAR
Sep 23, 2026 - ORBIMED ADVISORS LLC view on EDGAR
Sep 21, 2026 - Gary S. Koe view on EDGAR
Sep 21, 2026 - Nancy Stagliano view on EDGAR
Sep 21, 2026 - Graham Parry view on EDGAR
Sep 21, 2026 - Quehuong (Kathy) Dong view on EDGAR

Related companies with recent insider activity

Learn more

How to read insider buying signals: What an open-market purchase by an insider can and cannot tell you.
Insider activity in Health Care: Where ETRA's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow ETRA with a 7-day demo

ETRA on your watchlist
Every ETRA Form 4 filing on record
Up to 3 months of ETRA price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Open-market purchase

2,666,666

$40.00M

Other acquisition / disposition

23,927,906

Traded

Insider

Transaction

Security

Price

Value

Sep 21, 2026

Carl L. Gordon - Director

Other

Common Stock

2,002,310

-^{footnote F1}

Sep 21, 2026

Carl L. Gordon - Director

Other

Common Stock

1,087,934

-^{footnote F1}

Sep 21, 2026

Carl L. Gordon - Director

Other

Common Stock

1,703,314

-^{footnote F1}

Sep 21, 2026

Carl L. Gordon - Director

Open-market purchase

Common Stock

333,333^{footnote F2}

$15.00

$5.00M

Sep 21, 2026

Carl L. Gordon - Director

Other

Common Stock

758,279

-^{footnote F1}

Sep 21, 2026

Carl L. Gordon - Director

Open-market purchase

Common Stock

1,000,000^{footnote F2}

$15.00

$15.00M

Sep 21, 2026

Carl L. Gordon - Director

Other

Series A Convertible Preferred Stock

2,002,310

$0.00

Sep 21, 2026

Carl L. Gordon - Director

Other

Series B Convertible Preferred Stock

1,087,934

$0.00

Sep 21, 2026

Carl L. Gordon - Director

Other

Series C Convertible Preferred Stock

1,703,314

$0.00

Sep 21, 2026

Carl L. Gordon - Director

Other

Series C Convertible Preferred Stock

758,279

$0.00

Footnote F1 (price): Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering… Full note on SEC EDGAR
Footnote F2 (shares): Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

Sep 21, 2026

ORBIMED ADVISORS LLC - Director

Other

Common Stock

2,002,310

-^{footnote F1}

Sep 21, 2026

ORBIMED ADVISORS LLC - Director

Other

Common Stock

1,087,934

-^{footnote F1}

Sep 21, 2026

ORBIMED ADVISORS LLC - Director

Other

Common Stock

1,703,314

-^{footnote F1}

Sep 21, 2026

ORBIMED ADVISORS LLC - Director

Open-market purchase

Common Stock

333,333^{footnote F2}

$15.00

$5.00M

Sep 21, 2026

ORBIMED ADVISORS LLC - Director

Other

Common Stock

758,279

-^{footnote F1}

Sep 21, 2026

ORBIMED ADVISORS LLC - Director

Open-market purchase

Common Stock

1,000,000^{footnote F2}

$15.00

$15.00M

Sep 21, 2026

ORBIMED ADVISORS LLC - Director

Other

Series A Convertible Preferred Stock

2,002,310

$0.00

Sep 21, 2026

ORBIMED ADVISORS LLC - Director

Other

Series B Convertible Preferred Stock

1,087,934

$0.00

Sep 21, 2026

ORBIMED ADVISORS LLC - Director

Other

Series C Convertible Preferred Stock

1,703,314

$0.00

Sep 21, 2026

ORBIMED ADVISORS LLC - Director

Other

Series C Convertible Preferred Stock

758,279

$0.00

Footnote F1 (price): Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering… Full note on SEC EDGAR
Footnote F2 (shares): Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

Sep 21, 2026

Gary S. Koe - Officer

Other

Common Stock

63,656

-^{footnote F1}

Sep 21, 2026

Gary S. Koe - Officer

Other

Series A Convertible Preferred Stock

63,656

-^{footnote F1}

Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The… Full note on SEC EDGAR

Sep 21, 2026

Nancy Stagliano - Director

Other

Common Stock

255,635

-^{footnote F1}

Sep 21, 2026

Nancy Stagliano - Director

Other

Series A Convertible Preferred Stock

255,635

-^{footnote F1}

Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The… Full note on SEC EDGAR

Sep 21, 2026

Graham Parry - Officer

Other

Common Stock

85,504^{footnote F1}

-^{footnote F2}

Sep 21, 2026

Graham Parry - Officer

Other

Series A Convertible Preferred Stock

85,504^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): 7,125 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/4th of the Restricted Shares shall vest monthly commencing from September 2, 2026.
Footnote F2 (price): Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The… Full note on SEC EDGAR

Sep 21, 2026

Quehuong (Kathy) Dong - Officer

Other

Common Stock

455,484^{footnote F1}

-^{footnote F2}

Sep 21, 2026

Quehuong (Kathy) Dong - Officer

Other

Series A Convertible Preferred Stock

455,484^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): 73,147 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/13th of the Restricted Shares shall vest monthly commencing from September 16, 2026.
Footnote F2 (price): Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The… Full note on SEC EDGAR